ActoGeniX was founded in June 2006, as a spin-off from Vlamms Interuniversitair Instituut voor Biotechnologie (VIB) and Ghent University, to exploit its proprietary TopAct™ platform for oral administration of biopharmaceuticals. The Company is developing a broad and diverse portfolio of novel therapeutic products addressing major diseases with high unmet medical need, including gastrointestinal diseases, auto-immunity, allergy and metabolic diseases. ActoGeniX’ initial focus is on inflammatory bowel diseases and its lead product has already been successfully tested in a clinical trial with Crohn’s disease patients.